Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
The severity of COVID-19 (coronavirus disease 2019) disease caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has been associated with …
respiratory syndrome coronavirus-2 (SARS-CoV-2) has been associated with …
Comparative study of cytokine storm treatment in patients with COVID-19 pneumonia using immunomodulators
F Marc, CM Moldovan, A Hoza, S Magheru… - Journal of Clinical …, 2022 - mdpi.com
(1) Background: In patients hospitalized with COVID-19 pneumonia, especially moderate
and severe forms, a cytokine storm may occur, characterized by the worsening of symptoms …
and severe forms, a cytokine storm may occur, characterized by the worsening of symptoms …
Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
AM Al-Qaaneh, FH Al-Ghamdi, S AbdulAzeez… - Pharmaceutics, 2022 - mdpi.com
Severe acute respiratory coronavirus-2 (SARS-CoV-2) still presents a public threat and puts
extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment …
extra strain on healthcare facilities. Without an effective antiviral drug, all available treatment …
[PDF][PDF] Case study of tocilizumab in the treatment of macrophage activation syndrome secondary to systemic lupus erythematosus
Z Wang, C Sun, M Xu - International Journal of Frontiers in …, 2024 - francis-press.com
Macrophage activation syndrome (MAS) is a serious complication of autoimmune diseases,
with a potentially fatal risk, belonging to secondary hemophagocytic lymphohistiocytosis …
with a potentially fatal risk, belonging to secondary hemophagocytic lymphohistiocytosis …